DICE Therapeutics, Inc.
DICE · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $1 | $6 |
| % Growth | -100% | 30.4% | -85.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $1 | $1 | $6 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $63 | $37 | $20 | $16 |
| G&A Expenses | $26 | $12 | $5 | $4 |
| SG&A Expenses | $26 | $12 | $5 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $88 | $49 | $25 | $19 |
| Operating Income | -$88 | -$48 | -$24 | -$14 |
| % Margin | – | -4,231.4% | -2,748.7% | -234.6% |
| Other Income/Exp. Net | $4 | -$1 | -$0 | $1 |
| Pre-Tax Income | -$84 | -$49 | -$24 | -$13 |
| Tax Expense | -$2 | -$0 | $0 | $0 |
| Net Income | -$82 | -$48 | -$24 | -$13 |
| % Margin | – | -4,308.6% | -2,752.3% | -224.5% |
| EPS | -2.07 | -3.91 | -1.02 | -0.56 |
| % Growth | 47.1% | -283.3% | -82.1% | – |
| EPS Diluted | -2.07 | -3.91 | -1.02 | -0.56 |
| Weighted Avg Shares Out | 39 | 12 | 23 | 23 |
| Weighted Avg Shares Out Dil | 39 | 12 | 23 | 23 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $0 | $0 | $1 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $5 | $0 | $1 | $1 |
| EBITDA | -$83 | -$49 | -$23 | -$12 |
| % Margin | – | -4,324.4% | -2,651.8% | -211.4% |